70 related articles for article (PubMed ID: 34177793)
1. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of
Zheng W; Rui Z; Wang X; Li N; Tan J; Liu W
Front Endocrinol (Lausanne); 2021; 12():601960. PubMed ID: 34177793
[TBL] [Abstract][Full Text] [Related]
2. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer.
Ju N; Hou L; Song H; Qiu Z; Wang Y; Sun Z; Luo Q; Shen C
Eur Thyroid J; 2023 Aug; 12(4):. PubMed ID: 37022724
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Therapeutic Efficacy and Clinical Parameters Between Recombinant Human Thyroid Stimulating Hormone and Thyroid Hormone Withdrawal in High-Dose Radioiodine Treatment with Differentiated Thyroid Cancer.
Choi S; Na CJ; Kim J; Han YH; Kim HK; Jeong HJ; Sohn MH; Lim ST
Nucl Med Mol Imaging; 2015 Jun; 49(2):115-21. PubMed ID: 26085856
[TBL] [Abstract][Full Text] [Related]
4. A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate‑ and high‑risk differentiated thyroid cancer patients: a bi-center retrospective study.
Wen R; Zhao M; Chen C; Yang Y; Zhang B
Endocrine; 2023 Dec; ():. PubMed ID: 38085420
[TBL] [Abstract][Full Text] [Related]
5. Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation.
Lu L; Li Q; Ge Z; Lu Y; Lin C; Lv J; Huang J; Mu X; Fu W
Front Endocrinol (Lausanne); 2024; 15():1361683. PubMed ID: 38872967
[TBL] [Abstract][Full Text] [Related]
6. Basal or stimulated thyroglobulin in evaluating response to treatment in papillary thyroid carcinoma? A retrospective cohort study.
Barreto L; Ferreira DCG; Corrente JE; Soares CSP; Oliveira CC; Terra SA; Moriguchi SM; Koga KH; Tagliarini JV; da Silva Mazeto GMF
Hormones (Athens); 2024 Mar; 23(1):97-106. PubMed ID: 38015413
[TBL] [Abstract][Full Text] [Related]
7. Male Sex Is Not a Risk Factor for Prognosis in Postoperative Thyroid Cancer Patients: A Propensity Score Matching Study.
Zhou Y; Wang Y; Zhang Z; Yin X; Liu J; Zheng W
J Clin Endocrinol Metab; 2023 Nov; 108(12):3330-3337. PubMed ID: 37267432
[TBL] [Abstract][Full Text] [Related]
8. Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia.
Parvathareddy SK; Siraj AK; Annaiyappanaidu P; Siraj N; Al-Rasheed M; Al-Haqawi W; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2023; 14():1228049. PubMed ID: 37867506
[TBL] [Abstract][Full Text] [Related]
9. Determination of Diagnostic Features of Serum Thyroid Hormones and Thyroglobulin Ratios in Normothyroid Differentiated Thyroid Carcinoma Cases.
Aydogdu YF; Emreol U; Emre G; Buyukkasap C; Akin M
Sisli Etfal Hastan Tip Bul; 2023; 57(2):257-262. PubMed ID: 37899801
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy of Levothyroxine Sodium plus I 131 in the Treatment of Patients with Thyroidectomy and Its Effect on the Levels of Thyroglobulin and Thyrotropin.
Pang YL; Wang YP; Cheng K
Evid Based Complement Alternat Med; 2022; 2022():9557061. PubMed ID: 35958920
[TBL] [Abstract][Full Text] [Related]
11. Retracted: Clinical Efficacy of Levothyroxine Sodium plus I 131 in the Treatment of Patients with Thyroidectomy and Its Effect on the Levels of Thyroglobulin and Thyrotropin.
And Alternative Medicine EC
Evid Based Complement Alternat Med; 2023; 2023():9847675. PubMed ID: 38093870
[TBL] [Abstract][Full Text] [Related]
12. Analysis of factors influencing the clinical outcome after surgery and
Li Y; Rao M; Zheng C; Huang J; Fang D; Xiong Y; Yuan G
Front Endocrinol (Lausanne); 2022; 13():1015798. PubMed ID: 36313750
[TBL] [Abstract][Full Text] [Related]
13. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract][Full Text] [Related]
14. Stimulating thyroglobulin to TSH ratio predict long-term efficacy of
Yin X; Lu C; Sun D; Ji Y; Wang Y; Zheng H; Ma Z; Jia Q; Tan J; Zheng W
Endocrine; 2024 Jan; ():. PubMed ID: 38172344
[TBL] [Abstract][Full Text] [Related]
15. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
16. Random Forest for Predicting Treatment Response to Radioiodine and Thyrotropin Suppression Therapy in Patients With Differentiated Thyroid Cancer But Without Structural Disease.
Sa R; Yang T; Zhang Z; Guan F
Oncologist; 2024 Jan; 29(1):e68-e80. PubMed ID: 37669005
[TBL] [Abstract][Full Text] [Related]
17. [Insufficient elevation of TSH before therapy with I131 in a patient with metastatic differentiated thyroid carcinoma].
Ramírez Stieben LA; Queralt M; Sylvestre Begnis G; Polillo D; Barrenechea I
Rev Fac Cien Med Univ Nac Cordoba; 2023 Jun; 80(2):149-152. PubMed ID: 37402303
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
